This site is intended for health professionals only
Tuesday 27 September 2016 Instagram
Share |

Acambis reports positive flu vaccine results

Acambis reports positive flu vaccine results

A vaccine that could overcome the need for annual flu booster jabs has shown promising results in a Phase 1 clinical trial.

Experts from Acambis plc say the vaccine could present a potential tool in the fight against a flu pandemic.

"We are very excited about these new data and believe that this highly innovative vaccine could be very attractive in such a competitive field," said Chief Executive Officer of Acambis Ian Garland.

The vaccine, ACAM-FLU-A, is a recombinant vaccine linked to a Hepatitis B core protein that targets the M2e conserved region of all influenza "A" strains.

Phase 1 clinical trials show that ACAM-FLU-A is well tolerated and immunogenic.

Michael Watson, Acambis' executive vice president added: "M2e is one of the most discussed new approaches for influenza vaccination.

"We believe that these results confirm we have an approach worthy of further development."

Acambis

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?